Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2020

09.04.2020 | Laboratory Investigation

Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma

verfasst von: Brittany L. Voth, Panayiotis E. Pelargos, Natalie E. Barnette, Nikhilesh S. Bhatt, Cheng Hao Jacky Chen, Carlito Lagman, Lawrance K. Chung, Thien Nguyen, John P. Sheppard, Prasanth Romiyo, Sergey Mareninov, Valerie A. Kickhoefer, William H. Yong, Leonard H. Rome, Isaac Yang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glioblastoma (GBM) is the most common and malignant primary adult brain tumor. Current care includes surgical resection, radiation, and chemotherapy. Recent clinical trials for GBM have demonstrated extended survival using interventions such as tumor vaccines or tumor-treating fields. However, prognosis generally remains poor, with expected survival of 20 months after randomization. Chemokine-based immunotherapy utilizing CCL21 locally recruits lymphocytes and dendritic cells to enhance host antitumor response. Here, we report a preliminary study utilizing CPZ-vault nanoparticles as a vehicle to package, protect, and steadily deliver therapy to optimize CCL21 therapy in a murine flank model of GBM.

Methods

GL261 cells were subcutaneously injected into the left flank of eight-week-old female C57BL/6 mice. Mice were treated with intratumoral injections of either: (1) CCL21-packaged vault nanoparticles (CPZ-CCL21), (2) free recombinant CCL21 chemokine empty vault nanoparticles, (3) empty vault nanoparticles, or 4) PBS.

Results

The results of this study showed that CCL21-packaged vault nanoparticle injections can decrease the tumor volume in vivo. Additionally, this study showed mice injected with CCL21-packaged vault nanoparticle had the smallest average tumor volume and remained the only treatment group with a negative percent change in tumor volume.

Conclusions

This preliminary study establishes vault nanoparticles as a feasible vehicle to increase drug delivery and immune response in a flank murine model of GBM. Future animal studies involving an intracranial orthotopic tumor model are required to fully evaluate the potential for CCL21-packaged vault nanoparticles as a strategy to bypass the blood brain barrier, enhance intracranial immune activity, and improve intracranial tumor control and survival.
Literatur
1.
Zurück zum Zitat Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef
2.
Zurück zum Zitat Weller M et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385CrossRef Weller M et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385CrossRef
3.
Zurück zum Zitat Liau LM et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16(1):142CrossRef Liau LM et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16(1):142CrossRef
4.
Zurück zum Zitat Stupp R et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316CrossRef Stupp R et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316CrossRef
5.
Zurück zum Zitat Voth B et al (2015) Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment. J Clin Neurosci 22(7):1071–1076CrossRef Voth B et al (2015) Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment. J Clin Neurosci 22(7):1071–1076CrossRef
7.
Zurück zum Zitat Warnock RA et al (2000) The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med 191(1):77–88CrossRef Warnock RA et al (2000) The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med 191(1):77–88CrossRef
8.
Zurück zum Zitat Willimann K et al (1998) The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28(6):2025–2034CrossRef Willimann K et al (1998) The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28(6):2025–2034CrossRef
9.
Zurück zum Zitat Kar UK et al (2011) Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE 6(5):e18758CrossRef Kar UK et al (2011) Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE 6(5):e18758CrossRef
10.
Zurück zum Zitat Sharma S et al (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164(9):4558–4563CrossRef Sharma S et al (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164(9):4558–4563CrossRef
11.
Zurück zum Zitat Novak L et al (2007) Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 6(6):1755–1764CrossRef Novak L et al (2007) Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther 6(6):1755–1764CrossRef
12.
Zurück zum Zitat Yousefieh N et al (2009) Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2(1):59–67CrossRef Yousefieh N et al (2009) Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2(1):59–67CrossRef
13.
Zurück zum Zitat Liang CM et al (2007) Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 81(17):9502–9511CrossRef Liang CM et al (2007) Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 81(17):9502–9511CrossRef
14.
Zurück zum Zitat Baratelli F et al (2008) Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 6:38CrossRef Baratelli F et al (2008) Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 6:38CrossRef
15.
Zurück zum Zitat Stephen AG et al (2001) Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem 276(26):23217–23220CrossRef Stephen AG et al (2001) Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem 276(26):23217–23220CrossRef
16.
Zurück zum Zitat Wu A et al (2008) Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 17(1):173–184CrossRef Wu A et al (2008) Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 17(1):173–184CrossRef
17.
Zurück zum Zitat Lai CY et al (2009) Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer. ACS Nano 3(3):691–699CrossRef Lai CY et al (2009) Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer. ACS Nano 3(3):691–699CrossRef
18.
Zurück zum Zitat Champion CI et al (2009) A vault nanoparticle vaccine induces protective mucosal immunity. PLoS ONE 4(4):e5409CrossRef Champion CI et al (2009) A vault nanoparticle vaccine induces protective mucosal immunity. PLoS ONE 4(4):e5409CrossRef
19.
Zurück zum Zitat Hardee ME et al (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72(16):4119–4129CrossRef Hardee ME et al (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72(16):4119–4129CrossRef
20.
Zurück zum Zitat Morin-Brureau M et al (2015) Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Cancer Immunol Immunother 64(4):447–457CrossRef Morin-Brureau M et al (2015) Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Cancer Immunol Immunother 64(4):447–457CrossRef
21.
Zurück zum Zitat Noor S et al (2010) CCR7-dependent immunity during acute Toxoplasma gondii infection. Infect Immun 78(5):2257–2263CrossRef Noor S et al (2010) CCR7-dependent immunity during acute Toxoplasma gondii infection. Infect Immun 78(5):2257–2263CrossRef
22.
Zurück zum Zitat Ploix C, Lo D, Carson MJ (2001) A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity. J Immunol 167(12):6724–6730CrossRef Ploix C, Lo D, Carson MJ (2001) A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity. J Immunol 167(12):6724–6730CrossRef
23.
Zurück zum Zitat Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286(5447):2098–2102CrossRef Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286(5447):2098–2102CrossRef
24.
Zurück zum Zitat Gollmer K et al (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 114(3):580–588CrossRef Gollmer K et al (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 114(3):580–588CrossRef
25.
Zurück zum Zitat Nomura T, Hasegawa H (2000) Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res 20(6A):4073–4080PubMed Nomura T, Hasegawa H (2000) Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res 20(6A):4073–4080PubMed
26.
Zurück zum Zitat Sharma S et al (1997) Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4(12):1361–1370CrossRef Sharma S et al (1997) Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4(12):1361–1370CrossRef
27.
Zurück zum Zitat Patel MA et al (2014) The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 6(4):1953–1985CrossRef Patel MA et al (2014) The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 6(4):1953–1985CrossRef
28.
Zurück zum Zitat Ooi YC et al (2014) The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg 119:125–132CrossRef Ooi YC et al (2014) The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg 119:125–132CrossRef
29.
Zurück zum Zitat He Q et al (2018) Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells 7(4):24CrossRef He Q et al (2018) Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells 7(4):24CrossRef
30.
Zurück zum Zitat Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14CrossRef Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14CrossRef
31.
Zurück zum Zitat Lockman PR et al (2004) Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 12(9–10):635–641CrossRef Lockman PR et al (2004) Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 12(9–10):635–641CrossRef
32.
Zurück zum Zitat Sharma HS et al (2010) Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 106:359–364CrossRef Sharma HS et al (2010) Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 106:359–364CrossRef
Metadaten
Titel
Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma
verfasst von
Brittany L. Voth
Panayiotis E. Pelargos
Natalie E. Barnette
Nikhilesh S. Bhatt
Cheng Hao Jacky Chen
Carlito Lagman
Lawrance K. Chung
Thien Nguyen
John P. Sheppard
Prasanth Romiyo
Sergey Mareninov
Valerie A. Kickhoefer
William H. Yong
Leonard H. Rome
Isaac Yang
Publikationsdatum
09.04.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03479-8

Weitere Artikel der Ausgabe 3/2020

Journal of Neuro-Oncology 3/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.